Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

BACKGROUND: Molecularly targeted agents with anti-angiogenic activity, including bevacizumab, have demonstrated clinical activity in patients with advanced/metastatic hepatocellular carcinoma (HCC). This multicentre phase II study involving patients from several Asian countries sought to evaluate th...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hsu, C-H, Yang, T-S, Hsu, C, Toh, H C, Epstein, R J, Hsiao, L-T, Chen, P-J, Lin, Z-Z, Chao, T-Y, Cheng, A-L
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2010
Sujets:
Clinical Study
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2844032/
https://ncbi.nlm.nih.gov/pubmed/20160718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605580
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires